A61P 1 - Drugs for disorders of the alimentary tract or the digestive system

Patents for A61P 1 - Drugs for disorders of the alimentary tract or the digestive system (125,798)
12/2002
12/19/2002	WO2002100330A2 METHODS OF ADMINISTERING ANTI-TNFα ANTIBODIES
12/19/2002	WO2002100250A2 Wit 3.0, a novel gene to control soft tissue wound healing
12/19/2002	WO2002087583A3 Use of hiv-protease inhibitors to block cell migration and/or invasion, tissue infiltration and oedema formation
12/19/2002	WO2002085906A3 Phthalazinones derivatives useful as pde4/7 inhibitors
12/19/2002	WO2002080754A3 Methods for using annexin for detecting cell death in vivo and treating associated conditions
12/19/2002	WO2002078684A3 Carbon monoxide generating compounds for treatment of vascular, inflammatory and immune disorders
12/19/2002	WO2002070561A3 Nuclear hormone receptor ligand binding domain
12/19/2002	WO2002070560A3 Nuclear hormone receptor ligand binding domain
12/19/2002	WO2002070558A3 Nuclear hormone receptor ligand binding domain
12/19/2002	WO2002060894A3 Sulfonamide lactam inhibitors of factor xa
12/19/2002	WO2002059080A3 Trisubstituted carbocyclic cyclophilin binding compounds and their use
12/19/2002	WO2002055501A3 N-pyridyl carboxamide derivatives and pharmaceutical compositions containing them
12/19/2002	WO2002038500A3 Process for the rehydration of magaldrate powder
12/19/2002	WO2002005795A3 Pharmaceutical combinations for treatment and prevention of diabetes mellitus
12/19/2002	WO2001041748A3 Pharmaceutical combinations and their use in treating gastrointestinal disorders
12/19/2002	US20020193634 Disulfide derivatives useful for treating allergic diseases
12/19/2002	US20020193633 Mast cell stabilizers
12/19/2002	US20020193614 Treatment of cardiovascular disorders
12/19/2002	US20020193612 Nicotinamide biaryl derivatives useful as inhibitors of PDE4 isozymes
12/19/2002	US20020193605 Selectively inhibits action of N-type calcium channel; treatment of ischemic cerebrovascular disorders caused by cerebral infarction or intracerebral bleeding, Alzheimer's disease, AIDS related dementia, Parkinson's disease
12/19/2002	US20020193571 Wsx receptor agonist antibodies
12/19/2002	US20020193409 Prodrugs of anticancer agents employing substituted aromatic acids
12/19/2002	US20020193405 For prophylaxis and therapy of diseases, such as cell proliferation or apoptosis mediated diseases
12/19/2002	US20020193396 Sulfonamido ether substituted imidazoquinolines
12/19/2002	US20020193377 Quinazolines as MMP-13 inhibitors
12/19/2002	US20020192801 Human uridine diphosphate galactose-4-epimerase
12/19/2002	US20020192770 Beta-glucan products and extraction processes from cereals
12/19/2002	US20020192760 Nucleotide sequences coding membrane protein for use the diagnosis and treatment of asthma, parkinson's, heart defects, hypotension, urogenital disorders
12/19/2002	US20020192749 Human polynucleotides, polypeptides, and antibodies
12/19/2002	US20020192709 Detection of modulators of receptor binding activity; obtain sample containing receptor, incubate with modulator, monitor adjustment of binding activity of receptor
12/19/2002	US20020192682 Polynucleotides and polypeptides of the IFNalpha-2 gene
12/19/2002	US20020192306 Gastric acid secretion
12/19/2002	US20020192288 Methods and compositions for treating pain of the mucous membrane
12/19/2002	US20020192285 Controlled release pellet formulation
12/19/2002	US20020192282 Multilayer pharmaceutical product for release in the colon
12/19/2002	US20020192238 Proceture to use staphylococcal bacteria
12/19/2002	US20020192225 Methods of identifying bacterial genes that are incompatible with bacterial pathogenicity, and the use of such genes, such as cadA, to reduce pathogenicity in a bacteria or to combat pathogenic bacterial infections
12/19/2002	US20020192216 Therapeutic use
12/19/2002	US20020192202 Probiotic compounds derived from lactobacillus casei strain KE01
12/19/2002	US20020192162 Methods for using annexin for detecting cell death in vivo and treating associated conditions
12/19/2002	US20020192157 Treatment and diagnosis of macrophage mediated disease
12/19/2002	CA2487039A1 Combination therapies using vitamin b12 and interferon for treatment of viral, proliferative and inflammatory diseases
12/19/2002	CA2487038A1 Combination therapies using vitamin b12 and therapeutic agents for treatment of viral, proliferative and inflammatory diseases
12/19/2002	CA2450366A1 Controlled heat induced rapid delivery of pharmaceuticals from skin depot
12/19/2002	CA2450262A1 2,5-diarylpyrazines, 2,5-diarylpyridines and 2,5-diarylpyrimidines as crf1 receptor modulators
12/19/2002	CA2449944A1 Compositions comprising nitrofurantoin and uva ursi
12/19/2002	CA2449673A1 Orally administered dosage forms of gaba analog prodrugs having reduced toxicity
12/19/2002	CA2449602A1 Ns4 nucleic acids and polypeptides and methods of use for the treatment of body weight disorders
12/19/2002	CA2449544A1 Substituted 3-aryl-5-aryl-[1,2,4]-oxadiazoles and analogs
12/19/2002	CA2449517A1 Tissue-specific endothelial membrane proteins
12/19/2002	CA2449272A1 Intracellular signaling molecules
12/19/2002	CA2449256A1 Modulators of peroxisome proliferator activated receptors
12/19/2002	CA2448518A1 New compounds useful in reflux disease
12/19/2002	CA2445467A1 Quinuclidines-substituted-multi-cyclic-heteroaryls for the treatment of disease
12/18/2002	EP1267171A1 Cofactor-based screening method for nuclear receptor modulators
12/18/2002	EP1267167A1 Method for identifying HCV entry factors
12/18/2002	EP1266578A1 Feed preparation for animals, especially for poultry
12/18/2002	EP1266014A2 Multifunctional polypeptides comprising a binding site to an epitope of the nkg2d receptor complex
12/18/2002	EP1266012A2 Proteases
12/18/2002	EP1266001A2 Human transcription factors
12/18/2002	EP1266000A1 Chordin-like-2 molecules and uses thereof
12/18/2002	EP1265942A2 Use of poly(diallylamine) polymers
12/18/2002	EP1265919A2 G-protein associated molecules
12/18/2002	EP1265915A2 Novel compounds
12/18/2002	EP1265905A1 Il-8 receptor antagonists
12/18/2002	EP1265903A1 Thiepino[3,2-b]dihydropyridines and related compositions and methods
12/18/2002	EP1265900A1 1,5-disubstituted-3,4-dihydro-1h-pyrimido 4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases
12/18/2002	EP1265899A1 Pyrimidine compounds and their use as modulators of chemokine receptor activity
12/18/2002	EP1265896A1 4-hydroxy-1,8-naphthyridine-3-carboxamides as antiviral agents
12/18/2002	EP1265891A2 Novel lipoic acid heterocyclic or benzene derivatives, preparation and use thereof as medicines
12/18/2002	EP1265879A1 Allomorph isomer z hydrochloride of ranitidine
12/18/2002	EP1265870A1 New ccr5 modulators: benzimidazoles or benzotriazoles
12/18/2002	EP1265865A2 Difluorobutyric acid derivatives and their use as metalloprotease inhibitors
12/18/2002	EP1265863A1 Heterocyclic side chain containing metalloprotease inhibitors
12/18/2002	EP1265860A1 Amidino compound and salts thereof useful as nitric oxide synthase inhibitors
12/18/2002	EP1265859A2 Amidino compounds useful as nitric oxide synthase inhibitors
12/18/2002	EP1265853A1 Carboxylic acid derivatives as ip antagonists
12/18/2002	EP1265840A2 Novel amphipathic aldehydes and their use as adjuvants and immunoeffectors
12/18/2002	EP1265838A1 Novel fatty acid analogous
12/18/2002	EP1265639A1 The use of anticoagulant agents in the extracorporeal treatment of blood
12/18/2002	EP1265637A2 Compositions and methods for affecting osteogenesis
12/18/2002	EP1265623A2 Pharmaceutical compositions including alginates
12/18/2002	EP1265616A2 Hormone replacement therapy using a combination of conjugated estrogens and medroxyprogesterone acetate
12/18/2002	EP1265606A1 Cell adhesion inhibitors
12/18/2002	EP1265603A2 Il-8 receptor antagonists
12/18/2002	EP1265600A2 Headache and colic relief composition with asafetida and method of use thereof
12/18/2002	EP1265483A2 Use of phenylethylamine derivatives for the anitmicrobial treatment of surfaces
12/18/2002	EP1124814B1 Aromatic derivatives and iron complexes thereof for the use as normalising agents of the iron level
12/18/2002	EP1104420B1 Substituted 1,8-naphthyridin-4(1h)-ones as phosphodiesterase 4 inhibitors
12/18/2002	EP1086101B1 Beta-carboline compounds
12/18/2002	EP0934300B1 The preparation and use of ortho-sulfonamido heteroaryl hydroxamic acids as matrix metalloproteinase and tace inhibitors
12/18/2002	EP0882038B1 substituted n-methyl-n-(4-(piperidin-1-yl)-2-(aryl)butyl)benzamides useful for the treatment of allergic diseases
12/18/2002	EP0880526B1 Heterocycle-condensed morphinoid derivatives (ii)
12/18/2002	EP0873309B1 3-spiro-indolin-2-one derivatives as vasopressin and/or oxytocin receptor ligands
12/18/2002	EP0859784B1 Thio-substituted peptides as inhibitors for metalloproteinases and tnf liberation
12/18/2002	EP0769018B1 Helicobacter proteins and vaccines
12/18/2002	EP0760668B1 Use of magnesium-based products for the treatment or prophylaxis of neoplastic and autoimmune diseases
12/18/2002	CN1386132A Antimicrobial composition
12/18/2002	CN1385214A Dissolvent specially for omeprazole sodium injection
12/18/2002	CN1385211A Chinese medicine for treating heaptitis B and preparation method thereof and use of charred human hair

1 ... 917 918 919 920 921 922 923 924 925 926 927 928 929 930 931 932 933 934 935 936 937 ... 1258